Immatics, 2026 ESMO Yıllık Toplantısı'ndaki İki Sözlü Sunumda IMA402 PRAME Çift Spesifik ve IMA203CD8 PRAME Hücre Tedavisinin İleri Evre Solid Tümörlerdeki Klinik Aktivitesini Sundu

Immatics shared detailed clinical trial outcomes for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapy during two oral presentations at the 2026 ESMO Annual Meeting. The data highlighted sustained anti-tumor responses, notably achieving a confirmed overall response rate of 32 percent and a 91 percent one-year overall survival rate in advanced melanoma patients. These findings validate the therapeutic potential of targeting PRAME-expressing cancers with advanced immunotherapeutic modalities. Investigators emphasized the manageable safety profile observed across diverse solid tumor types. The presentations mark a meaningful step forward in the clinical validation of the company's proprietary cell and bispecific pipeline. Healthcare analysts anticipate further trial updates as Immatics advances these oncology assets toward late-stage development.